UK launch of oral diabetes pill Foundayo signals new competition in weight‑loss drug market
Executive summary: Foundayo, a new daily pill that treats diabetes and aids weight loss, became available in UK pharmacies on private prescription from the coming Monday (announced 2026‑08‑24). It provides an oral alternative to injectable GLP‑1 therapies, potentially expanding patient access and altering market dynamics for diabetes and obesity drugs.
Who is involved: The pharmaceutical company behind Foundayo, UK pharmacies dispensing the product, and pharmacists warning about counterfeit GLP‑1 products.
Likely next: Monitoring of uptake and NHS evaluation, continued vigilance against counterfeit GLP‑1 medicines, and possible pursuit of broader reimbursement pathways.
The Guardian reports that Foundayo, a once‑daily tablet for type 2 diabetes that also promotes weight loss, will be sold on private prescription in UK pharmacies starting the coming Monday. Pharmacists welcomed the option for patients but flagged an existing counterfeit GLP‑1 problem that could be exacerbated by the new product. The launch adds an oral alternative to injectable GLP‑1 therapies such as semaglutide and tirzepatide, potentially broadening access and shifting prescribing patterns.
Timeline
- — Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy (PR Newswire)
- — New daily diabetes pill that helps with weight loss launches in UK pharmacies (The Guardian — Science)
Analysis — what this means
Likely next events
- Foundayo to be available in UK pharmacies from the coming Monday (announced 2026‑08‑24)
- Pharmacists warn of ongoing counterfeit GLP‑1 problem accompanying the launch
Sectors affected
- Diabetes therapeutics
- Weight‑loss/obesity drugs
- UK retail pharmacy
Regulatory implications
- Increased scrutiny by UK MHRA on counterfeit GLP‑1 products following Foundayo launch
Historical parallels
- Oral semaglutide (Rybelsus) launched in the US in 2019 as first oral GLP‑1 diabetes drug
- Liraglutide (Saxenda) approved for weight loss in the EU in 2015
Sources
- New daily diabetes pill that helps with weight loss launches in UK pharmacies — The Guardian — Science
- Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy — PR Newswire
Related cases
- GLP-1-driven shift toward protein‑centric meals creates new demand for high‑protein foods and supplements
- High earners are the only group that nets grocery savings after paying for costly GLP‑1 weight‑loss drugs, making the medication a regressive ‘tax on being thin’
- Cathie Wood’s Ark Invest is increasing its stake in a GLP-1 pharmaceutical stock that has appreciated 1,600% over the last decade
- Prescription drug sales projected to jump 62% to €1.7 trillion, driven by obesity and autoimmune therapies
- Weight‑loss drugs are reshaping UK and US apparel spending as users buy new clothes after slimming down